Artificial Intelligence Is Future Of Postmarketing Surveillance, US FDA’s Marks Says
CBER director’s vision for a national safety surveillance system includes use of AI and natural language processing to enable near-real time signal detection from adverse event reports.
You may also be interested in...
Head of agency’s inspectorate stresses need to invest in new IT infrastructure for manufacturing site inspections. New FDA Inspectional Affairs Council leads the charge.
President Biden’s budget request would add $1.63bn in mandatory funding to the FDA budget in FY 2023.
Agency re-evaluating criteria for certain human cells, tissues and cellular and tissue-based products (HCT/Ps) that are not ideally regulated as BLAs; industry suggests a 2014 guidance which created an alternative pathway for cord blood products could serve as potential template.